CTLA4 and myeloid sarcoma: Fukazawa and colleagues have found that the CTLA-4 exon 1 polymorphism was similar when comparing Japanese MS patients and controls; however, this study has shown that this CTLA-4 polymorphism could modulate the prognosis of MS patients [136].